• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用钇-90选择性内放射治疗作为肝切除的桥梁:一项为期5年的单中心经验。

Use of selective internal radiation therapy with yttrium-90 as a bridge to liver resection: a 5-year single-center experience.

作者信息

Kalra Aryan, Rowcroft Alistair, Trinder Matthew, Ballal Mohammed, Bhandari Mayank

机构信息

School of Medicine, The University of Western Australia, Perth, Western Australia, Australia.

Department of General Surgery, Fiona Stanley Hospital, Perth, Western Australia, Australia.

出版信息

J Gastrointest Surg. 2024 Dec;28(12):1970-1975. doi: 10.1016/j.gassur.2024.09.007. Epub 2024 Sep 10.

DOI:10.1016/j.gassur.2024.09.007
PMID:39265776
Abstract

BACKGROUND

Selective internal radiation therapy (SIRT) with yttrium-90 (Y-90) has been historically reserved for unresectable liver malignancy. Evidence is emerging for the use of SIRT to increase future liver remnant (FLR), allowing for the resection of previously inoperable disease.

METHODS

This was a 5-year retrospective review of all patients undergoing SIRT with Y-90 at a tertiary institute. Patient demographics, clinicopathologic data, surgical details, and postoperative outcomes were reviewed. The primary outcome, safety of liver resection after SIRT, was evaluated with 90-day morbidity and mortality.

RESULTS

A total of 134 SIRT procedures were performed on 113 patients. Post-SIRT complications occurred in 18 patients (15.9%), with a single 30-day mortality. In addition, 17 patients underwent SIRT with the intent to augment FLR for liver resection. After SIRT, mean hepatic mebrofenin extraction and FLR increased from 2.5%/min/m and 30.5% to 4.2%/min/m and 52.5% (P = .01 and P < .0001, respectively). Ten patients underwent resection, and there were 2 intraoperative complications. The median time from SIRT to resection was 5.2 months. The 90-day postoperative morbidity was 20% (n = 2), and complications were analyzed according to the Clavien-Dindo II classification scale. There was no 30-day or 90-day postoperative mortality.

CONCLUSION

Post-SIRT liver resection is a challenging procedure with low postoperative mortality and morbidity.

摘要

背景

钇-90(Y-90)选择性内放射治疗(SIRT)在历史上一直用于不可切除的肝脏恶性肿瘤。越来越多的证据表明,使用SIRT可增加未来肝脏残余量(FLR),从而能够切除先前无法手术的疾病。

方法

这是一项对某三级医疗机构中所有接受Y-90 SIRT治疗的患者进行的为期5年的回顾性研究。回顾了患者的人口统计学、临床病理数据、手术细节和术后结果。以90天的发病率和死亡率评估主要结局,即SIRT后肝切除的安全性。

结果

共对113例患者进行了134次SIRT手术。18例患者(15.9%)出现SIRT后并发症,30天内有1例死亡。此外,17例患者接受SIRT的目的是增加FLR以进行肝切除。SIRT后,平均肝美布芬宁摄取率和FLR分别从2.5%/分钟/米和30.5%增加到4.2%/分钟/米和52.5%(P分别为0.01和<0.0001)。10例患者接受了手术,术中出现2例并发症。从SIRT到手术的中位时间为5.2个月。术后90天发病率为20%(n = 2),并根据Clavien-Dindo II分类量表分析并发症。术后30天和90天均无死亡。

结论

SIRT后肝切除是一项具有挑战性的手术,术后死亡率和发病率较低。

相似文献

1
Use of selective internal radiation therapy with yttrium-90 as a bridge to liver resection: a 5-year single-center experience.使用钇-90选择性内放射治疗作为肝切除的桥梁:一项为期5年的单中心经验。
J Gastrointest Surg. 2024 Dec;28(12):1970-1975. doi: 10.1016/j.gassur.2024.09.007. Epub 2024 Sep 10.
2
Liver Resection After Selective Internal Radiation Therapy with Yttrium-90: Safety and Outcomes.钇-90选择性内放射治疗后的肝切除术:安全性与疗效
J Gastrointest Cancer. 2020 Mar;51(1):152-158. doi: 10.1007/s12029-019-00221-0.
3
The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres.《SIR-Spheres 术后研究(P4S)》:先前接受钇 90 树脂微球选择性内部放射治疗的肝切除或肝移植患者的安全性回顾性分析。
Ann Surg Oncol. 2017 Sep;24(9):2465-2473. doi: 10.1245/s10434-017-5950-z. Epub 2017 Jun 26.
4
Liver Resection for Colorectal Hepatic Metastases after Systemic Chemotherapy and Selective Internal Radiation Therapy with Yttrium-90 Microspheres: A Systematic Review.结直肠癌肝转移行全身化疗联合钇[90]微球选择性内放射治疗后行肝切除术:系统评价。
Dig Surg. 2019;36(4):273-280. doi: 10.1159/000490111. Epub 2018 Jun 8.
5
Single-institution experience with selective internal radiation therapy (SIRT) for the treatment of unresectable colorectal liver metastases.单机构采用选择性内照射治疗(SIRT)治疗不可切除的结直肠癌肝转移的经验。
Ir J Med Sci. 2019 Feb;188(1):43-53. doi: 10.1007/s11845-018-1773-6. Epub 2018 Mar 6.
6
Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.选择性肝内钇-90放射性栓塞治疗(90Y-SIRT)与最佳支持治疗对全身治疗难治的不可切除转移性黑色素瘤肝转移患者的疗效比较:安全性和有效性队列研究
Am J Clin Oncol. 2017 Feb;40(1):27-34. doi: 10.1097/COC.0000000000000109.
7
(90) Y radiation lobectomy: Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes.(90) Y 射线肝叶切除术:肝肿瘤患者手术切除后及未来肝残余体积较小时的预后情况。
J Surg Oncol. 2016 Jul;114(1):99-105. doi: 10.1002/jso.24269. Epub 2016 Apr 22.
8
Hepatic volume changes post-selective internal radiation therapy with Y microspheres.选择性内放射治疗后肝体积的变化。
J Med Imaging Radiat Oncol. 2020 Jun;64(3):347-352. doi: 10.1111/1754-9485.13040. Epub 2020 May 6.
9
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.钇[90Y]树脂微球选择性内放射治疗与索拉非尼治疗局部进展期不可切除肝细胞癌的疗效和安全性比较(SARAH):一项开放标签随机对照 3 期临床试验。
Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26.
10
Liver Resection After Selective Internal Radiation Therapy with Yttrium-90 is Safe and Feasible: A Bi-institutional Analysis.钇-90选择性内放射治疗后肝切除术安全可行:一项双机构分析
Ann Surg Oncol. 2017 Apr;24(4):906-913. doi: 10.1245/s10434-016-5697-y. Epub 2016 Nov 22.

引用本文的文献

1
Hepatocellular Carcinoma and Health-Related Quality of Life: A Systematic Review of Outcomes From Systemic Therapies.肝细胞癌与健康相关生活质量:系统疗法结局的系统评价
Int J Hepatol. 2025 Apr 7;2025:1083642. doi: 10.1155/ijh/1083642. eCollection 2025.